Page 69 - 2019_01-Haematologica-web

Myelodysplastic Syndromes
Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker
of outcome
Julia Stomper,1 Gabriele Ihorst,2 Stefan Suciu,3 Philipp N. Sander,1,4 Heiko Becker,1 Pierre W. Wijermans,5 Christoph Plass,6,7 Dieter Weichenhan,6 Emmanuel Bissé,8 Rainer Claus1,9 and Michael Lübbert1,10
1Department of Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, Germany; 2Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Germany; 3EORTC Headquarters, Brussels, Belgium; 4Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA; 5Department of Hematology, Haga Hospital, The Hague, the Netherlands; 6DKFZ Heidelberg, Division of Epigenomics and Cancer Risk Factors, Heidelberg, Germany; 7German Cancer Research Consortium (DKTK), Heidelberg, Germany; 8Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and Medical Center, University of Freiburg, Germany; 9Department of Internal Medicine II, Hematology/Oncology, Augsburg Medical Center, Germany and 10German Cancer Research Consortium (DKTK), Freiburg, Germany
ABSTRACT
Hematologic responses to hypomethylating agents are often delayed in patients with myelodysplastic syndrome or acute myeloid leukemia. Fetal hemoglobin is a potential novel bio- marker of response: recently, we demonstrated that a high fetal hemo- globin level prior to decitabine treatment was associated with superior outcome. Here we investigated whether early fetal hemoglobin induc- tion during decitabine treatment also had prognostic value, and studied the potential of decitabine to induce erythroid differentiation and fetal hemoglobin expression in vitro. Fetal hemoglobin levels were measured by high-performance liquid chromatography in patients with higher-risk myelodysplastic syndrome (n=16) and acute myeloid leukemia (n=37) before treatment and after each course of decitabine. Levels above 1.0% were considered induced. Patients achieving complete or partial remis- sion as best response had attained a median fetal hemoglobin of 1.9% after two courses of treatment, whereas the median value in patients who did not reach complete or partial remission was 0.8% (P=0.015). Fetal hemoglobin induction after two courses of decitabine treatment was associated with early platelet doubling (P=0.006), and its subsequent decrease with hematologic relapse. In patients with myelodysplastic syndrome, induction of fetal hemoglobin after course 2 of treatment was associated with longer overall survival: median of 22.9 versus 7.3 months in patients with or without induction of fetal hemoglobin, respectively [hazard ratio=0.2 (95% confidence interval: 0.1-0.9); P=0.03]. In vitro decitabine treatment of two bi-potential myeloid leukemia cell lines (K562 and HEL) resulted in induction of an erythroid (not megakaryocyt- ic) differentiation program, and of fetal hemoglobin mRNA and protein, associated with GATA1 gene demethylation and upregulation. In conclu- sion, fetal hemoglobin may provide a useful dynamic biomarker during hypomethylating agent therapy in patients with myelodysplastic syn- drome or acute myeloid leukemia.
Ferrata Storti Foundation
Haematologica 2019 Volume 104(1):59-69
Correspondence:
michael.luebbert@uniklinik-freiburg.de
Received: December 30, 2017. Accepted: August 28, 2018. Pre-published: August 31, 2018.
doi:10.3324/haematol.2017.187278
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/104/1/59
©2019 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
haematologica | 2019; 104(1)
59
ARTICLE